GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Innovotech Inc (TSXV:IOT) » Definitions » LT-Debt-to-Total-Asset

Innovotech (TSXV:IOT) LT-Debt-to-Total-Asset : 0.07 (As of Sep. 2024)


View and export this data going back to 2003. Start your Free Trial

What is Innovotech LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Innovotech's long-term debt to total assests ratio for the quarter that ended in Sep. 2024 was 0.07.

Innovotech's long-term debt to total assets ratio increased from Sep. 2023 (0.00) to Sep. 2024 (0.07). It may suggest that Innovotech is progressively becoming more dependent on debt to grow their business.


Innovotech LT-Debt-to-Total-Asset Historical Data

The historical data trend for Innovotech's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Innovotech LT-Debt-to-Total-Asset Chart

Innovotech Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
LT-Debt-to-Total-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.36 0.02 0.03 - -

Innovotech Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
LT-Debt-to-Total-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - 0.09 0.07

Innovotech LT-Debt-to-Total-Asset Calculation

Innovotech's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

LT Debt to Total Assets (A: Dec. 2023 )=Long-Term Debt & Capital Lease Obligation (A: Dec. 2023 )/Total Assets (A: Dec. 2023 )
=0/1.217
=0.00

Innovotech's Long-Term Debt to Total Asset Ratio for the quarter that ended in Sep. 2024 is calculated as

LT Debt to Total Assets (Q: Sep. 2024 )=Long-Term Debt & Capital Lease Obligation (Q: Sep. 2024 )/Total Assets (Q: Sep. 2024 )
=0.1/1.439
=0.07

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Innovotech  (TSXV:IOT) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.


Innovotech LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Innovotech's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Innovotech Business Description

Traded in Other Exchanges
N/A
Address
2011 - 94 Street, Suite L131, Edmonton, AB, CAN, T6N 1H1
Innovotech Inc is a Canada-based company that provides solutions to client biofilm problems through its biofilm contract research department. The core activities of the company are sales of its products, conducting contract research for outside customers, and research and development to identify products for future commercialization. The products of the company include human and fungal biofilm susceptibility tests, a seed treatment designed to combat bacterial and fungal diseases, and an assay used in growing microbial biofilms for research purposes. Geographically, the firm has a business presence in the United States, Canada, and the Rest of the world of which the majority of the revenue is derived from the United States.
Executives
James Gregory Timourian Senior Officer
Bradley Alan Clark Director
Alan Clyde Hayes Savage 10% Security Holder
Craig Milne Director
David Shong-tak Tam Director
Bernard Grobbelaar Director